Goldengate and Infinium genotyping certification for Integragen

24 June 2007

Concurrent with the annual European Human Genetics Conference in Nice, France, USA-based Illumina says that French firm IntegraGen SA, a personalized health care company focused on the development and commercialization of molecular diagnostic tests for complex diseases and provider of genetic services, has received Illumina Certified Service Provider (CSPro) certification for GoldenGate and Infinium genotyping technologies.

The GoldenGate assay is Illumina's first array-based platform that combines high-sample throughput, high multiplexing, and single-site CpG resolution for DNA methylation profiling. The Infinium Whole-Genome Genotyping BeadArray solution offers single or multi-sample BeadChip formats and high-density architecture with the flexibility to add additional custom SNP Assays, the US firm says.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight